Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Pediatric Endocrinology

Treatment Strategies: Surgery and Medical Therapies

At a Glance

X-linked acrogigantism is usually managed urgently with a combination of safe pituitary surgery and specialist medicines. Pegvisomant may control growth when surgery is incomplete or delayed, while hormone replacement may be needed if pituitary function is lost.

Deciding on a treatment path for X-linked acrogigantism (X-LAG) is a complex process that involves balancing the need to stop aggressive growth with the long-term health of your child’s pituitary gland. Because X-LAG starts so early and is so aggressive, the “wait and see” approach is rarely an option [1][2]. Instead, most families and doctors use a combination of surgery and specialized medications to bring hormone levels back into a safe range [3][4].

Surgery: The First Line of Defense

When a child has a visible pituitary tumor (macroadenoma) and surgery is deemed safe based on the tumor’s anatomy and the child’s age, surgery is usually the primary treatment [1]. The goal is a maximal safe resection to remove as much of the overactive tissue as possible to immediately lower growth hormone (GH) levels, while minimizing harm.

  • The Procedure: Most surgeries are performed through the nose (transsphenoidal surgery), though very young infants may sometimes require different approaches [5][6].
  • The Challenge: In X-LAG, the overactive tissue is often spread throughout the gland or is very sticky and difficult to separate from healthy tissue [1]. To stop the growth effectively, surgeons may need to perform an extensive anterior pituitary resection (removing most of the front part of the gland) [1][7]. Doing so requires balancing this against the risks of cerebrospinal fluid (CSF) leaks, infection, and vascular or visual injury.
  • The Trade-off: While surgery can stop the rapid height gain, it frequently leads to hypopituitarism—a condition where the remaining pituitary gland cannot produce enough of the other essential hormones your child needs for life [3][8]. Transient or permanent diabetes insipidus can also occur.

Managing Post-Surgical Risks

Because surgery for X-LAG is often extensive, parents must be prepared for the immediate and long-term “replacement” phase. Hormone replacement is not automatic; it is prescribed only when blood tests confirm a deficiency:

  1. Adrenal and Thyroid Support: If the surgery removes the cells that signal the adrenal and thyroid glands, your child will need daily doses of hydrocortisone and levothyroxine [8][2]. Suspected adrenal insufficiency must be assessed and treated under specialist direction, often before starting thyroid replacement.
  2. Diabetes Insipidus (DI): This is a temporary or permanent condition where the body cannot balance fluids, leading to extreme thirst and frequent urination. It is managed with a medication called desmopressin (DDAVP) [8][9].
  3. Growth and Puberty: Later in life, children may also need help starting puberty or maintaining healthy growth if the “normal” growth hormone cells were removed [2]. These decisions are made only after controlling GH/IGF-1 excess.

Medical Therapies: When Surgery Isn’t Enough

If surgery cannot remove the entire tumor safely, if hormone levels remain high, or if surgery must be delayed, medications are used as a primary strategy or secondary “bridge” to control the disease.

  • Pegvisomant: This medication is often considered highly effective for X-LAG [1]. It works by blocking the GH receptor, essentially “locking the door” so the excess hormone cannot tell the bones to grow [9]. In several small pediatric series, pegvisomant successfully normalized growth in reported X-LAG patients who received it [1][5]. However, it does not lower GH levels in the blood or shrink the pituitary mass, meaning it cannot substitute for urgent treatment of optic compression. It is often off-label for infants and requires daily injections, along with specialist monitoring of liver function, injection sites, and serial MRIs.
  • Somatostatin Analogues (e.g., Octreotide, Lanreotide): These are common for adult acromegaly, but they often provide only partial control in X-LAG [3][9]. They may help shrink a tumor slightly, but they rarely stop the growth acceleration entirely on their own [10][3]. Requires monitoring of gallbladder (gallstones) and blood sugar.
  • Cabergoline: If your child also has very high prolactin levels, this oral medication may be added as an “adjunct” (extra help) alongside other treatments [4][9]. Efficacy for GH control alone is minimal.

A Note on Radiotherapy

Radiotherapy (using targeted radiation to kill tumor cells) is generally reserved as a “rescue” option if surgery and medications both fail [6]. While it can be very effective, doctors are cautious about using it in infants and toddlers because of potential long-term risks to brain development, vision, delayed hypopituitarism, and the risk of secondary tumors later in life [11][12].

The journey with X-LAG is often a marathon, not a sprint. While the initial treatments are intensive, the goal is always to find the combination that allows your child to grow at a healthy, predictable rate while maintaining a high quality of life.

Common questions in this guide

Is surgery usually the first treatment for X-linked acrogigantism?
When a child has a visible pituitary tumor and surgery is safe for the tumor’s location and the child’s age, surgery is usually the primary treatment. Surgeons often use an approach through the nose and aim to remove as much overactive tissue as possible without causing avoidable harm. The tumor may be spread through the gland, so complete removal is not always possible.
What hormone problems can happen after X-LAG surgery?
Extensive pituitary surgery can cause hypopituitarism, meaning the gland no longer makes enough of several essential hormones. Blood tests guide whether a child needs hydrocortisone for adrenal support or levothyroxine for thyroid support. Temporary or permanent diabetes insipidus can cause marked thirst and frequent urination and is treated with desmopressin.
How does pegvisomant help children with X-LAG?
Pegvisomant blocks the action of excess growth hormone at its receptor, which can help bring growth under control even when blood growth hormone remains high. It does not shrink the pituitary tumor or lower the growth hormone level in the blood, so it cannot replace urgent treatment when the tumor is pressing on the optic pathways. Children taking it need specialist follow-up, daily injections, liver-function monitoring, and regular MRI scans; use in infants may be off-label.
Why might doctors choose one X-LAG medicine over another?
Pegvisomant often provides stronger control of growth in reported X-LAG cases, while octreotide and lanreotide may offer only partial control and may slightly shrink the tumor. Cabergoline may be added when prolactin is very high, but it usually has little effect on growth hormone by itself. Somatostatin medicines require monitoring for gallstones and blood-sugar changes, whereas pegvisomant requires liver monitoring.
When is radiotherapy considered for X-LAG?
Radiotherapy is generally a rescue option when surgery and medicines have not controlled the tumor or hormone excess. Doctors are cautious about using it in infants and toddlers because long-term effects can include delayed loss of pituitary function, effects on brain development or vision, and a risk of later secondary tumors. A specialist team should discuss potential benefits and risks for the individual child.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my child a candidate for a 'gross total resection' (complete removal), or is the tumor in a location where we should only aim for 'debulking' (partial removal)?
  2. 2.What is your plan for monitoring my child's sodium levels and urine output immediately after surgery to watch for diabetes insipidus?
  3. 3.If we start medication after surgery, what is the specific reason for choosing a somatostatin analogue over pegvisomant, given that many X-LAG cases respond better to the latter?
  4. 4.How will we determine if the dose of pegvisomant needs to be increased, and what liver function tests are required for monitoring?
  5. 5.If radiotherapy is ever suggested, what are the long-term risks for my child's cognitive development and vision?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    X-linked acrogigantism syndrome: clinical profile and therapeutic responses.

    Beckers A, Lodish MB, Trivellin G, et al.

    Endocrine-related cancer 2015; (22(3)):353-67 doi:10.1530/ERC-15-0038.

    PMID: 25712922
  2. 2

    Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome.

    Naves LA, Daly AF, Dias LA, et al.

    Endocrine 2016; (51(2)):236-44 doi:10.1007/s12020-015-0804-6.

    PMID: 26607152
  3. 3

    A Chinese Case of X-Linked Acrogigantism and Systematic Review.

    Liang H, Gong F, Liu Z, et al.

    Neuroendocrinology 2021; (111(12)):1164-1175 doi:10.1159/000512240.

    PMID: 33049741
  4. 4

    Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.

    Rodd C, Millette M, Iacovazzo D, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(5)):1927-30 doi:10.1210/jc.2015-4366.

    PMID: 26982009
  5. 5

    The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism.

    Daly AF, Beckers A

    Endocrine reviews 2024; (45(5)):737-754 doi:10.1210/endrev/bnae014.

    PMID: 38696651
  6. 6

    Pituitary gigantism: a retrospective case series.

    Creo AL, Lteif AN

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(5)):597-602.

    PMID: 26887033
  7. 7

    An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations.

    Trivellin G, Hernández-Ramírez LC, Swan J, Stratakis CA

    Best practice & research. Clinical endocrinology & metabolism 2018; (32(2)):125-140 doi:10.1016/j.beem.2018.02.004.

    PMID: 29678281
  8. 8

    Childhood acromegaly due to X-linked acrogigantism: long term follow-up.

    Gordon RJ, Bell J, Chung WK, et al.

    Pituitary 2016; (19(6)):560-564 doi:10.1007/s11102-016-0743-0.

    PMID: 27631333
  9. 9

    Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism.

    Burren CP, Williams G, Coxson E, Korbonits M

    JCEM case reports 2023; (1(3)):luad028 doi:10.1210/jcemcr/luad028.

    PMID: 37908565
  10. 10

    Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism.

    Caruso M, Mazzatenta D, Asioli S, et al.

    Frontiers in endocrinology 2024; (15()):1345363 doi:10.3389/fendo.2024.1345363.

    PMID: 38481440
  11. 11

    [Pituitary adenomas].

    Honegger J, Nasi-Kordhishti I, Giese S

    Der Nervenarzt 2019; (90(6)):568-577 doi:10.1007/s00115-019-0708-4.

    PMID: 30997549
  12. 12

    Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

    Perry A, Graffeo CS, Marcellino C, et al.

    Journal of neurological surgery. Part B, Skull base 2018; (79(1)):91-114 doi:10.1055/s-0038-1625984.

    PMID: 29404245

This page explains treatment options for children with X-linked acrogigantism for informational purposes only and does not constitute medical advice. Discuss surgery, medicines, and hormone replacement with your child’s specialist team.

Get notified when new evidence is published on X-linked acrogigantism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.